Lobe Competitors

OTC Stocks . USA . 
Stock . Lobe Sciences
LOBEF Stock  USD 0.04  0  10.98%   
Analyzing Lobe Sciences competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Lobe Sciences to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Lobe Sciences Correlation with its peers.

Lobe Sciences vs General Cannabis Correlation

Very good diversification

The correlation between Lobe Sciences and CANN is -0.46 (i.e., Very good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Lobe Sciences and CANN in the same portfolio, assuming nothing else is changed.

Moving together with Lobe OTC Stock

  0.61TAK Takeda PharmaceuticalPairCorr

Moving against Lobe OTC Stock

  0.59PBCRY Bank Central AsiaPairCorr
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Lobe Sciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.000.0452.09
Details
Intrinsic
Valuation
LowRealHigh
0.000.0352.08
Details
Naive
Forecast
LowNextHigh
00.06297.72
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
-0.010.030.07
Details

Lobe Sciences Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Lobe Sciences and its competitors represents the degree of relationship between the price movements of corresponding otcs. A correlation of about +1.0 implies that the price of Lobe and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Lobe Sciences does not affect the price movement of the other competitor.

High positive correlations

AUSAF
+ 1.0
VDQSF
BUDZ
+ 0.55
CVSI
BUDZ
+ 0.51
CBIH
CVSI
+ 0.47
PCLOF
CANN
+ 0.45
TWSI
CVSI
+ 0.34
CBIH
  

High negative correlations

PCLOF
- 0.54
TWSI
CANN
- 0.51
PCLOF
BBRRF
- 0.45
CBIH
BUDZ
- 0.42
BBRRF
CVSI
- 0.33
BBRRF
CANN
- 0.21
CVSI

Risk-Adjusted Indicators

There is a big difference between Lobe OTC Stock performing well and Lobe Sciences OTC Stock doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Lobe Sciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
VDQSF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
AUSAF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
CBIH  12.06  1.65  0.08  2.84  11.05 
(26.56)
 40.00 
(20.00)
 78.57 
IONKF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
TWSI  5.25 (0.29) 0.00 (0.04) 0.00 
 0.00 
 9.09 
(16.00)
 130.78 
PCLOF  17.87  4.88  0.27  1.72  13.12 
(32.93)
 26.67 
(20.69)
 290.00 
BBRRF  6.05  0.46  0.03 (2.64) 7.86 
(12.94)
 16.83 
(11.50)
 57.95 
CVSI  9.40  1.97  0.10  1.16  8.81 
(33.08)
 25.00 
(20.00)
 153.57 
BUDZ  7.51  0.15  0.02  0.12  8.35 
(10.58)
 20.47 
(16.50)
 52.70 
CANN  4.75 (0.05) 0.00 (0.01) 0.00 
 0.00 
 9.73 
(9.09)
 42.10 

Lobe Sciences Competitive Analysis

The better you understand Lobe Sciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Lobe Sciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Lobe Sciences' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
LOBEF VDQSF AUSAF CBIH TWSI PCLOF BBRRF CVSI BUDZ CANN
 10.98 
 0.04 
Lobe
 0.00 
 0 
Gnomestar
 0.00 
 0.0001 
Australis
 25.00 
 0.0005 
Cannabis
 20.00 
 0.09 
Tristar
 26.67 
 0.08 
Pharmacielo
 5.26 
 0.01 
Blueberries
 12.40 
 0.04 
CVSI
 11.00 
 0.03 
Weed
 9.42 
 0.04 
General
Market Volatility
(90 Days Market Risk)
Out of control
Very steady
Very steady
Out of control
Out of control
Out of control
Out of control
Out of control
Out of control
Out of control
Market Performance
(90 Days Performance)
Solid
Weakest
Weakest
Mild
Weakest
Good
Mild
Fair
Weak
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Moderate
Hazard
Moderate
Unknown
Risky
Small
Strong
Low
Moderate
Small
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Over Valued
Under Valued
Fairly Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Sell
Not Rated
Strong Sell
Strong Sell
Strong Sell
Cautious Hold
Strong Sell
Cautious Hold
Strong Sell
Strong Sell
Current Ratio
2.23
0.11
0.69
N/A
0.1
0.81
0.41
0.93
0.59
0.61
Net Asset
1.75 M
1.22 M
N/A
N/A
3.07 M
35.96 M
3.59 M
18.07 M
1.96 M
22.02 M
Profit Margin
N/A
N/A
N/A
N/A
-1.77
N/A
N/A
-0.85
N/A
-0.59
EBITDA
(4.11 M)
(499.37 K)
(17.68 M)
N/A
(4.02 M)
(24.75 M)
(4.05 M)
(14.35 M)
(2.67 M)
(6.6 M)
Current Valuation
(6.77 M)
1.25 M
4.89 M
N/A
11.48 M
38.68 M
3.89 M
5.53 M
13.24 M
35.32 M
Price To Book
0.76
N/A
0.4
N/A
N/A
4.28
132.07
3.57
13.02
2.67
Operating Margin
N/A
-6.81
-2.05
N/A
-1.07
-3.22
-14.36
-0.93
N/A
-0.0938
Retained Earnings
N/A
N/A
N/A
N/A
(35.5 M)
N/A
N/A
(21.65 M)
(7.24 M)
(33.4 M)
Current Asset
N/A
N/A
N/A
N/A
1.66 M
N/A
N/A
15.84 M
2 K
1.42 M
Beta
2.64
1.68
1.12
N/A
-0.65
2.85
1.36
1.0
1.65
1.09
Number Of Employees
3
3
10
N/A
35
6
23
69
2
77
Shares Outstanding
76.97 M
85.41 M
260.91 M
N/A
28.66 M
151.41 M
163.81 M
150.1 M
123.48 M
114.17 M
Cash Flow From Operations
(2.73 M)
(129.87 K)
(14.17 M)
N/A
(4.48 M)
(20.07 M)
(1.68 M)
(7.49 M)
(568.91 K)
(2.65 M)
Total Debt
N/A
867.24 K
2.45 M
N/A
N/A
7.14 M
1.57 M
1.4 M
947.8 K
5.91 M
Return On Equity
-2.8
N/A
-0.92
N/A
N/A
-0.98
-2.12
-2.36
-1.27
-0.73
Z Score
-6.6
N/A
1.8
N/A
-23.7
2.4
-2.1
2.6
-0.3
0.4
Return On Asset
-0.65
-0.46
-0.17
N/A
-0.64
-0.26
-0.26
-0.52
-0.49
-0.0299
Book Value Per Share
0.001
-0.025
0.097
N/A
-0.52
0.061
N/A
0.009
0.008
0.076
Current Liabilities
N/A
N/A
N/A
N/A
17.24 M
N/A
N/A
3.01 M
269 K
17.93 M
Total Asset
1.75 M
1.22 M
N/A
N/A
3.07 M
35.96 M
3.59 M
18.07 M
1.96 M
22.02 M
Debt To Equity
N/A
148.3
0.053
N/A
N/A
0.71
4.08
0.74
0.78
0.99
Target Price
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.05
N/A
N/A
Shares Owned By Institutions
N/A
N/A
0.03
N/A
N/A
5.71
N/A
N/A
N/A
N/A
Market Capitalization
2.01 M
630.08 K
8.54 M
N/A
315.3 K
31.8 M
4.68 M
7.85 M
11.83 M
18.61 M
Price To Earning
1.34
-0.77
N/A
N/A
-0.1
N/A
13.85
54.89
-23.33
-0.58
Price To Sales
7.72
6.63
1.24
N/A
0.0789
7.25
23.72
0.28
N/A
1.23
Net Income
(12.25 M)
(875.56 K)
(50.09 M)
N/A
(8.87 M)
(26.63 M)
(5.15 M)
(15.55 M)
(2.84 M)
(8.87 M)
Earnings Per Share
-0.31
-0.007
-0.051
N/A
-0.27
-0.12
-0.026
-0.13
-0.021
-0.094
Shares Owned By Insiders
2.85
11.9
28.32
N/A
N/A
3.5
68.53
2.01
55.72
82.81
Revenue
N/A
266.5 K
9.47 M
N/A
5.55 M
1.94 M
138.75 K
20.05 M
N/A
5.93 M
Working Capital
N/A
N/A
N/A
N/A
(15.58 M)
N/A
N/A
12.83 M
(267 K)
(16.51 M)
Cash And Equivalents
1.38 M
18.06 K
727.69 K
N/A
336 K
1.17 M
467.13 K
1.11 M
821.09 K
1.07 M
Cash Per Share
0.04
N/A
N/A
N/A
0.01
0.01
N/A
0.01
0.01
0.01
Gross Profit
841.56 K
(270.56 K)
5.87 M
N/A
239 K
(4.17 M)
(245.45 K)
8.62 M
N/A
1.49 M
Day Typical Price
0.0385
0.0012
1.0E-4
5.0E-4
0.0687
0.076
0.012
0.0429
0.0345
0.0358
Accumulation Distribution
5246.54
N/A
N/A
386060.0
78467.41
N/A
N/A
55566.67
9887.21
8109.8
Daily Balance Of Power
(0.68)
0.0
0.0
0.5
(0.38)
9.2 T
9.2 T
(1.24)
0.4925
0.5439
Period Momentum Indicator
(0)
N/A
N/A
1.0E-4
(0.02)
0.016
6.0E-4
(0.01)
0.0033
0.0031
Rate Of Daily Change
0.89
1.0
1.0
1.25
0.8
1.27
1.05
0.88
1.11
1.09
Day Median Price
0.0395
0.0012
1.0E-4
5.0E-4
0.059
0.076
0.012
0.0425
0.0351
0.0358
Price Action Indicator
(0.01)
N/A
N/A
1.0E-4
0.018
0.008
3.0E-4
(0)
(0.0001)
0.0018
Relative Strength Index
53.35
N/A
N/A
48.38
35.05
57.92
54.85
49.98
42.7
47.94
Coefficient Of Variation
321.23
N/A
N/A
1015.46
(13,188)
755.66
2279.3
967.08
4142.82
(855,068)
Mean Deviation
173.15
N/A
N/A
12.06
5.25
17.87
6.05
9.4
7.51
4.75
Jensen Alpha
87.59
N/A
N/A
1.65
(0.29)
4.88
0.4586
1.97
0.1515
(0.05)
Total Risk Alpha
71.26
N/A
N/A
0.6095
(1.18)
2.64
(0.20)
0.8072
(0.41)
(0.47)
Sortino Ratio
1.93
N/A
N/A
0.084
N/A
0.2675
0.0294
0.0958
0.0196
N/A
Downside Variance
2127.86
N/A
N/A
379.2
N/A
344.95
190.46
438.6
101.26
N/A
Standard Deviation
286.37
N/A
N/A
17.18
16.73
37.96
10.5
19.94
10.49
7.33
Kurtosis
5.25
N/A
N/A
0.8412
14.62
37.31
3.79
22.4
0.8498
5.26
Potential Upside
900.0
N/A
N/A
40.0
9.09
26.67
16.83
25.0
20.47
9.73
Treynor Ratio
2.63
N/A
N/A
2.84
(0.04)
1.72
(2.64)
1.16
0.1213
(0.01)
Maximum Drawdown
1083.64
N/A
N/A
78.57
130.78
290.0
57.95
153.57
52.7
42.1
Variance
82009.87
N/A
N/A
295.18
279.82
1440.85
110.33
397.56
110.04
53.74
Market Risk Adjusted Performance
2.64
N/A
N/A
2.85
(0.03)
1.73
(2.63)
1.17
0.1313
(0)
Risk Adjusted Performance
0.2382
N/A
N/A
0.0818
0.004
0.1068
0.0415
0.0854
0.027
0.0089
Skewness
2.62
N/A
N/A
0.8279
1.55
5.41
0.3206
3.81
0.5456
0.4533
Semi Deviation
30.43
N/A
N/A
11.05
N/A
13.12
7.86
8.81
8.35
N/A
Information Ratio
0.3111
N/A
N/A
0.0952
(0.01)
0.1309
0.0386
0.1006
0.0188
(0.01)
Value At Risk
(90.00)
N/A
N/A
(20.00)
(16.00)
(20.69)
(11.50)
(20.00)
(16.50)
(9.09)
Expected Short fall
(202.03)
N/A
N/A
(26.56)
N/A
(32.93)
(12.94)
(33.08)
(10.58)
N/A
Downside Deviation
46.13
N/A
N/A
19.47
N/A
18.57
13.8
20.94
10.06
N/A
Semi Variance
926.03
N/A
N/A
122.09
N/A
172.01
61.72
77.65
69.66
N/A

Lobe Sciences Competition Performance Charts

Five steps to successful analysis of Lobe Sciences Competition

Lobe Sciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Lobe Sciences in relation to its competition. Lobe Sciences' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Lobe Sciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Lobe Sciences' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Lobe Sciences, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Lobe Sciences position

In addition to having Lobe Sciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Target Outcome ETFs Thematic Idea Now

Target Outcome ETFs
Target Outcome ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Target Outcome ETFs theme has 86 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Target Outcome ETFs Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Lobe OTC Stock

Lobe Sciences financial ratios help investors to determine whether Lobe OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Lobe with respect to the benefits of owning Lobe Sciences security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY